SCHEMBL1670312

SCHEMBL1670312

CCOC(Cc1ccccc1)C(=O)O

nearest known ligand 0.69

Predicted protein targets (top 4)

geneUniProtsupporting neighboursconfidence
PPARA Q07869 17/20 0.69
PPARG P37231 13/20 0.69
PPARD Q03181 6/20 0.69
SRR Q9GZT4 2/20 0.62

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4993002 1.00 PPARA (0.69) PPARAPPARGPPARDSRR
SCHEMBL15246753 0.87 PPARA (0.56) PPARAPPARGPPARDSRR
Ethylene SCHEMBL5331457 0.87 PPARA (0.65) PPARAPPARGPPARDSRR
SCHEMBL16415813 0.87 PPARA (0.92) PPARAPPARGPPARD
SCHEMBL5993963 0.87 PPARA (0.92) PPARAPPARGPPARD
SCHEMBL5608022 0.87 PPARA (0.92) PPARAPPARGPPARD
SCHEMBL543815 0.86 PPARA (0.72) PPARAPPARGPPARD
SCHEMBL17680422 0.86 PPARA (0.68) PPARAPPARGPPARD
SCHEMBL3541115 0.86 MMP8 (0.56) PPARAPPARGPPARDSRR
SCHEMBL5543269 0.86 PPARA (0.72) PPARAPPARGPPARD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-101133040-A Novel heterocyclic oxime derivatives, method for preparing same and use thereof as hypoglycaemic or hypolipidemic agents SERVIER LAB (FR) 2008-02-27 CN claimed
CN-101133028-A Novel heterocyclic oxime derivatives, method for preparing same and pharmaceutical compositions containing same SERVIER LAB (FR) 2008-02-27 CN claimed
CN-1558758-A Novel pyrrole compound with blood fat and cholesterol reducing activity, preparation method thereof, pharmaceutical composition containing same and medical application thereof 2004-12-29 CN claimed
CN-110099898-A compound and use thereof 优曼尼蒂治疗公司 2019-08-06 CN disclosed
CN-106068256-A Benzodiazepine derivatives, compositions and methods for treating cognitive impairment 艾吉恩生物股份有限公司 2016-11-02 CN disclosed
US-20160296592-A1 Methods and Compositions for the Treatment of Proteinuric Diseases THE GENERAL HOSPITAL CORPORATION 2016-10-13 US disclosed
CN-102123763-B Prodrugs of methyl hydrogen fumarate, pharmaceutical compositions thereof, and methods of use thereof XENOPORT, INC. (US) 2014-10-08 CN disclosed
CN-102448933-B Indole Derivatives as PBR Ligands GE HEALTHCARE LTD 2014-07-02 CN disclosed
CN-103517897-A Synthesis of cyclopentaquinazolines ONYX PHARMA INC 2014-01-15 CN disclosed
EP-2488500-A1 SPIROPIPERIDINE COMPOUNDS AND PHARMACEUTICAL USE THEREOF FOR TREATING DIABETES Eli Lilly and Company (US) 2012-08-22 EP disclosed
CN-102448933-A Indole Derivatives as PBR Ligands GE HEALTHCARE LTD 2012-05-09 CN disclosed
EP-1237854-A1 COMMINUTED FORM OF (S)-2-ETHOXY -3- 4-(2- 4-METHANESULFONYLOXYPHENYL ETHOXY) PHENYL] PROPANOIC ACID AstraZeneca AB (SE) 2002-09-11 EP disclosed
CN-1352639-A Novel tricyclic compounds and their use in medicine, process for their production and pharmaceutical composition containing them REDDY RESEARCH FOUNDATION (IN) 2002-06-05 CN disclosed
WO-2001040169-A1 COMMINUTED FORM OF (S)-2-ETHOXY -3-[4-(2- {4-METHANESULFONYLOXYPHENYL} ETHOXY) PHENYL] PROPANOIC ACID ASTRAZENECA AB (SE) 2001-06-07 WO disclosed
EP-1084102-A1 NEW 3-ARYL PROPIONIC ACID DERIVATIVES AND ANALOGS AstraZeneca AB (SE) 2001-03-21 EP disclosed
CN-1280575-A Novel tricyclic compounds and their use as medicaments, process for their preparation and pharmaceutical compositions containing them REDDY CHEMINOR INC (IN) 2001-01-17 CN disclosed
EP-0758013-B1 Liquid crystalline optical film, compensating film for liquid crystal display and liquid crystal display NIPPON OIL CO LTD (JP) 2000-10-11 EP disclosed
WO-1999062871-A1 NEW 3-ARYL PROPIONIC ACID DERIVATIVES AND ANALOGS ASTRAZENECA AB (SE) 1999-12-09 WO disclosed
US-5855971-A Liquid crystalline optical film, compensating film for liquid crystal display comprising the liquid crystalline optical film, and liquid crystal display having the compensating film NIPPON OIL COMPANY, LIMITED (JP) 1999-01-05 US disclosed
EP-0758013-A1 Liquid crystalline optical film, compensating film for liquid crystal display and liquid crystal display NIPPON OIL COMPANY, LIMITED (JP) 1997-02-12 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160296592-A1 Methods and Compositions for the Treatment of Proteinuric Diseases ITGB3, PLAUR, PROC PPARA 3054/4885PPARG 2468/4885PPARD 2223/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.